ZEVRA THERAPEUTICS, INC. (ZVRA)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenue, net | 25,881 | 20,401 | 3,695 | 4,449 |
| Impairment of intangible assets | 58,710 | - | - | - |
| Selling, general and administrative | 20,782 | 19,545 | 16,208 | 12,604 |
| Research and development | 3,433 | 3,258 | 10,945 | 10,521 |
| Total operating expenses | 24,215 | 22,803 | 27,153 | 23,125 |
| Cost of product revenue | 12,379 | 1,345 | 2,303 | 3,573 |
| Intangible asset amortization | 1,616 | - | - | - |
| Intangible asset amortization | - | 1,615 | 1,545 | 1,546 |
| Loss from operations | -71,039 | -5,362 | -27,306 | -23,795 |
| Us-gaap_fairvalueadjustmentofwarrants | - | - | 4,746 | -5,779 |
| Interest and other income, net | 2,378 | - | 1,049 | 270 |
| Fair value adjustment related to warrant and cvr liability | 747 | - | - | - |
| Fair value adjustment related to investments | 2 | - | -90 | -1 |
| Interest expense | 2,009 | - | 2,312 | 2,110 |
| Gain on sale of prv | 148,325 | - | - | - |
| Total other income | 147,945 | 3,445 | -5,919 | 3,940 |
| Income (loss) before income taxes | 76,906 | -1,917 | -33,225 | -19,855 |
| Income tax expense | 2,199 | 1,182 | - | 70 |
| Net income (loss) | 74,707 | -3,099 | -33,225 | -19,925 |
| Basic (in dollars per share) | 1.24 | -0.06 | -0.69 | -0.48 |
| Basic (in shares) | 54,780,938 | 54,095,543 | 47,808,817 | 41,899,087 |
| Diluted (in dollars per share) | 1.21 | - | - | - |
| Diluted (in shares) | 56,324,903 | - | - | - |